This trial will test if tolvaptan can help prevent or delay kidney failure in children with ARPKD.
2 Primary · 4 Secondary · Reporting Duration: From Enrollment to 2 years of age
Experimental Treatment
20 Total Participants · 1 Treatment Group
Primary Treatment: Tolvaptan (OPC-41061) · No Placebo Group · Phase 3
Age 28 - 12 · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: